Interstitial Lung Disease Drug Pipeline: 86 Assets by Phase

How many interstitial lung disease drugs are in each phase of development?

Douglas Insights counts 15 interstitial lung disease candidates in Phase III, 17% of the 86 assets in development; Phase II holds 52 and Phase I holds 19.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each interstitial lung disease asset appears in exactly one row. The 238 trials still recruiting or running carry 45% of the 525 registered trials in scope.

Which approved interstitial lung disease medicines are still in trials?

2 medicines already on the market are still being tested in interstitial lung disease Phase IV trials; Pirfenidone has the most, with 28 registered trials.

Post-approval interstitial lung disease trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many interstitial lung disease trials are recruiting patients now?

132 interstitial lung disease trials are recruiting patients and 46 more have not started recruiting yet, out of 525 interventional trials in scope; together they make up 34% of the trial base.

Terminated, suspended and withdrawn interstitial lung disease trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the interstitial lung disease pipeline?

GlaxoSmithKline leads the interstitial lung disease pipeline with 3 candidates; the top 5 sponsors hold 15% of the 86 assets, and 72 sponsors run at least one.

Industry sponsors lead 249 of the 525 interstitial lung disease trials (47%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the interstitial lung disease pipeline?

Mechanism and drug-type classification for the 86 interstitial lung disease candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What interstitial lung disease trial readouts are coming next?

22 interstitial lung disease candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many interstitial lung disease readouts fall in each quarter?

41 interstitial lung disease candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 13, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most interstitial lung disease trials?

United States hosts the most interstitial lung disease trials, with sites in 248 of the 525 studies (47%); trials in scope run in 65 countries in all.

A multinational interstitial lung disease trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are interstitial lung disease drugs being tested?

248 of the 525 interstitial lung disease trials (47%) have a site in the United States, 169 (32%) in Europe and 127 (24%) in China; 48 of the 86 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational interstitial lung disease trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the interstitial lung disease pipeline since the last update?

Since 3 Oct 2026, the interstitial lung disease pipeline count moved by +1 assets to 86, Phase III moved by 0 and the trial base by 0.

How does Douglas Insights count the interstitial lung disease pipeline?

Douglas Insights read 525 interventional trials registered on ClinicalTrials.gov for the conditions "Lung Diseases, Interstitial", "interstitial lung disease" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 86 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the interstitial lung disease pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage